#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Juvenile idiopathic arthritis Hereditary spastic paraplegia Malignant oligodendroglioma Familial amyotrophic lateral sclerosis Palmoplantar pustulosis Penile cancer Immune-mediated renal disorder Ischaemic stroke Cholestatic pruritus Mantle cell lymphoma Philadelphia chromosome positive Chronic inflammatory demyelinating polyradiculoneuropathy Neuroendocrine tumour of the lung B-cell lymphoma Malignant central nervous system neoplasm More trials…

    Learn about Rare Diseases

    Pemphigoid – Life with Disease Cerebral arteriovenous malformation haemorrhagic – Trials in Disease Primary mediastinal large B-cell lymphoma – Basic Information SAPHO syndrome – Basic Information Hereditary hypophosphataemic rickets – Basic Information Niemann-Pick disease – Basic Information Familial haemophagocytic lymphohistiocytosis – Trials in Disease Hypereosinophilic syndrome – Diagnostics Glomerulonephritis membranoproliferative – Basic Information Paroxysmal nocturnal haemoglobinuria – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Maridebart Cafraglutide Rupatadine H2-Receptor Antagonists TUB-030 VALACICLOVIR HYDROCHLORIDE Gallium (68Ga) Rbp030.2 Floxuridine Fipaxalparant Ropivacaine Paraffin White Soft Gen1053 Sodium S-Lactate Solution E2814 PAPAVERINE HYDROCHLORIDE Baricitinib GSKVX000000070965 Xanthum Gum Bimatoprost Cimetidine Hydrochloride More therapies…

    Learn about Your Condition

    Post-acute COVID-19 syndrome Craniosynostosis Hypochromic anaemia Hypertension Acute leukaemia Pancreatic carcinoma stage IV Cerebral palsy Pigmentary glaucoma Acute HIV infection Organ donor Agitation postoperative Myxofibrosarcoma Myotonic dystrophy Urticaria Papillary thyroid cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Clinique Pasteur

Clinique Pasteur

45 Avenue De Lombez, Cs 27617, Toulouse, 31076, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Hormonal Treatment with Leuprorelin Acetate for Prostate Cancer Patients at High Risk of Recurrence After Surgery

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Leuprorelin Acetate
    France

  • Study on Chemotherapy and Hormone Therapy for Women Over 70 with ER-Positive, HER2-Negative Breast Cancer Using Cyclophosphamide and Drug Combination

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer female
    Investigated Drugs:
    • Cyclophosphamide
    • Docetaxel
    • Doxorubicin
    Belgium France

  • Study of Elafibranor in Adults with Primary Biliary Cholangitis Who Don’t Respond Well to or Cannot Tolerate Ursodeoxycholic Acid Treatment

    Not recruiting

    3 1
    Investigated Drugs:
    • Elafibranor
    Czechia France Germany Italy Poland Romania +1

  • Study of Rivaroxaban versus standard care in patients with excessive atrial ectopy or short atrial runs who have high risk of blood clots

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Atrial fibrillation
    Investigated Drugs:
    • Lactose Monohydrate
    • Rivaroxaban
    France

  • A Study of Cabazitaxel and Pelvic Radiation Therapy Combined with Hormone Treatment for Patients with High-Risk Localized Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Cabazitaxel
    Belgium France Spain

  • Study of Ribociclib and Letrozole for Patients with High-Risk Estrogen Receptor-Positive, HER2-Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Letrozole
    • Ribociclib
    France Spain

  • Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Olaparib
    Austria Belgium France Germany Hungary Iceland +6

  • Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Evolocumab
    Austria Belgium Bulgaria Czechia Denmark Estonia +16

  • Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Fulvestrant
    France

  • Study on the Effectiveness of Ethanol in Treating Hypertension in Patients with Uncontrolled High Blood Pressure

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hypertension
    Investigated Drugs:
    • Ethanol, Anhydrous
    Austria Belgium France Germany Ireland The Netherlands +1
Previous Page
1 … 3 4 5 6
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!